AstraZeneca has a strong history delivering antiviral treatments and vaccines, for example against SARS-CoV-2, seasonal flu and respiratory syncytial virus (RSV).
The SARS-CoV-2 pandemic has shown that broad-acting agents with activity against a wide range of viruses could be critical for controlling rapid viral spread. Through modulation of host-proteins that are often shared by multiple virus families, or by targeting host-pathways and cellular proteins that are hijacked by viruses.
This challenge is seeking novel solutions for broad spectrum antiviral agents and treatments. A novel technology, small, or large molecules, or some other breakthrough idea. The ultimate goal would be a broad-spectrum prophylactic or therapeutic with activity against known and emerging viruses.